Experimental GLS1 Inhibitor IACS-6274 Shrinks Tumors in Advanced Treatment-Resistant Ovarian Cancer Phase I Trial
An experimental drug, IACS-6274, shrank tumors in most patients with advanced, treatment-resistant ovarian cancer in an early-phase clinical trial, with nine of 13 evaluable patients achieving confirmed partial responses, researchers reported at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona.
The drug, an oral glutaminase-1 (GLS1) inhibitor developed by The University of Texas MD Anderson Cancer Center’s Therapeutics Discovery division, was combined with standard doses of bevacizumab and paclitaxel chemotherapy in 21-day treatment cycles. All 14 patients enrolled in the Phase 1 trial had tumors that had stopped responding to standard-of-care treatment, including platinum-based chemotherapy, according to Newswise.
Three patients had stable disease, and 11 of the 13 evaluable patients had disease control 12 weeks after starting the trial. Principal investigator Timothy A. Yap, MD, PhD, professor of Investigational Cancer Therapeutics and head of clinical development in UT MD Anderson’s Therapeutics Discovery division, presented the data.
The therapy was well-tolerated, with no dose-limiting toxicities, Newswise reported. More severe effects included higher-grade neutropenia, elevated blood pressure and anemia, but these were successfully treated.
Most cancers develop resistance to the bevacizumab-paclitaxel combination within about a year by becoming overly dependent on the nutrient glutamine, Newswise reported. Previous attempts to broadly inhibit the enzymes that give cancers access to glutamine, GLS1 and GLS2, failed and caused unwanted side effects. IACS-6274 was designed to selectively inhibit GLS1 without affecting glutaminase-2, an enzyme important in several biological processes, and to be better absorbed than earlier GLS inhibitors.
Eight of the 14 patients had tumors lacking the enzyme ASNS, leaving them completely dependent on glutamine for survival. Six of those eight achieved radiological partial responses, Inside Precision Medicine reported.
An analysis of tumor and blood samples also showed the treatment reshaped the tumor microenvironment toward greater immune system activation, according to Inside Precision Medicine. Fifteen more patients are due to receive the treatment as part of the trial, followed by another 15 if results remain positive; the trial is also investigating IACS-6274 in other cancer types and combinations, Newswise reported.